Data gathered: December 12
AI Stock Analysis - Recursion Pharmaceuticals (RXRX)
Analysis generated December 8, 2024. Powered by Chat GPT.
Recursion Pharmaceuticals is a biotechnology company leveraging advanced computational techniques and machine learning to accelerate drug discovery and development processes. The company's core focus is to bridge the gap between biological data and potential therapeutic drugs, thereby expediting the timeline from research to clinical application. With a strong emphasis on using technology to drive innovation, Recursion Pharmaceuticals is positioned at the intersection of biotechnology, artificial intelligence, and data science.
Stock Alerts - Recursion Pharmaceuticals (RXRX)
 |
Recursion Pharmaceuticals | December 12 Price is down by -5.2% in the last 24h. |
|
Recursion Pharmaceuticals | December 10 Price is down by -5.6% in the last 24h. |
|
Recursion Pharmaceuticals | December 9 Price is up by 12.3% in the last 24h. |
|
Recursion Pharmaceuticals | December 9 Reddit mentions are up by 114% in the last 24h. |
Alternative Data for Recursion Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 24 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 45,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 80 | Sign up | Sign up | Sign up |
| Patents | 35 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 12 | Sign up | Sign up | Sign up |
| Facebook Followers | 666 | Sign up | Sign up | Sign up |
| Reddit Mentions | 16 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 45 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,247 | Sign up | Sign up | Sign up |
| Twitter Followers | 12,853 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 2,940 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | N/A | Sign up | Sign up | Sign up |
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
| Price | $6.98 |
| Target Price | Sign up |
| Volume | 12,700,000 |
| Market Cap | $3.22B |
| Year Range | $5.7 - $10.05 |
| Dividend Yield | 0% |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early TrialsDecember 12 - Yahoo Entertainment |
|
 |
Charles Schwab Investment Management Inc. Boosts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)December 9 - ETF Daily News |
|
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCDecember 8 - ETF Daily News |
|
Traders Buy High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)December 7 - ETF Daily News |
|
MetLife Investment Management LLC Acquires 16,405 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)December 7 - ETF Daily News |
 |
Recursion Pharmaceuticals CEO sells $285,600 in stockDecember 6 - Investing.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 26M | 55M | -29M | -96M | -93M | -0.340 |
| Q2 '24 | 14M | 46M | -32M | -98M | -96M | -0.400 |
| Q1 '24 | 14M | 46M | -32M | -91M | -89M | -0.390 |
| Q4 '23 | 11M | 45M | -34M | -93M | -94M | -0.420 |
| Q3 '23 | 11M | 43M | -33M | -93M | -90M | -0.430 |
Insider Transactions View All
| Gibson Christopher filed to sell 736,633 shares at $7.1. December 6 '24 |
| Gibson Christopher filed to sell 762,656 shares at $7.4. November 15 '24 |
| Secora Michael filed to sell 1,499,631 shares at $7.7. November 14 '24 |
| Borgeson Blake filed to sell 7,066,113 shares at $7.6. November 14 '24 |
| Marriott Tina filed to sell 521,138 shares at $6.3. October 28 '24 |
Similar companies
Read more about Recursion Pharmaceuticals (RXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Recursion Pharmaceuticals?
The Market Cap of Recursion Pharmaceuticals is $3.22B.
What is the current stock price of Recursion Pharmaceuticals?
Currently, the price of one share of Recursion Pharmaceuticals stock is $6.98.
How can I analyze the RXRX stock price chart for investment decisions?
The RXRX stock price chart above provides a comprehensive visual representation of Recursion Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Recursion Pharmaceuticals shares. Our platform offers an up-to-date RXRX stock price chart, along with technical data analysis and alternative data insights.
Does RXRX offer dividends to its shareholders?
As of our latest update, Recursion Pharmaceuticals (RXRX) does not offer dividends to its shareholders. Investors interested in Recursion Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Recursion Pharmaceuticals?
Some of the similar stocks of Recursion Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.